Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT06321601
- Locations
- 🇨🇦
Stollery Childrens Hospital, Edmonton, Alberta, Canada
🇭🇺Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar, Szeged, Hungary
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
- Conditions
- Sjögren’s Syndrome
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-07-04
- Target Recruit Count
- 151
- Registration Number
- 2023-507680-19-00
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research-S Vineyard Ave, Mesa, Arizona, United States
🇺🇸Arizona Arthritis and Rheumatology Associates -4550 E Bell Rd, Phoenix, Arizona, United States
🇺🇸Neurovations Research, Napa, California, United States
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- Conditions
- Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 927
- Registration Number
- NCT06311721
- Locations
- 🇺🇸
Precision NextGen Oncology and Research Center, Beverly Hills, California, United States
🇺🇸TOI Clinical Research, Cerritos, California, United States
🇺🇸Cancer and Blood Specialty Clinic (CBSC), Los Alamitos, California, United States
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
- Conditions
- Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7000
- Registration Number
- NCT06295679
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Rocatinlimab vial injectionCombination Product: Rocatinlimab prefilled syringe
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT06268860
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc. - Madison, Madison, Wisconsin, United States
🇺🇸Fortrea Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States
🇺🇸Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 450
- Registration Number
- NCT06252649
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona, United States
🇺🇸Providence Saint Jude Medical Center, Fullerton, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT06248619
- Locations
- 🇺🇸
Catalina Eye Care - NVISION - PPDS, Tucson, Arizona, United States
🇺🇸Shiley Eye Center University of California at San Diego, La Jolla, California, United States
🇺🇸Amy Patel Jain MD Inc., Newport Beach, California, United States
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 435
- Registration Number
- NCT06245408
- Locations
- 🇺🇸
Arizona Research Clinic PLLC, Chandler, Arizona, United States
🇺🇸Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln, Flagstaff, Arizona, United States
🇺🇸Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert, Arizona, United States
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 262
- Registration Number
- NCT06229145
- Locations
- 🇺🇸
The University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Orthopedic Physicians Alaska - Rheumatology and Infusion, Anchorage, Alaska, United States
🇺🇸Arizona Arthritis and Rheumatology, Tucson, Arizona, United States
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 151
- Registration Number
- NCT06224192
- Locations
- 🇺🇸
Kern Research Inc, Bakersfield, California, United States
🇺🇸Long Beach Research Institute, Long Beach, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States